Impact of treatment modality on overall survival in localized ductal prostate adenocarcinoma: A national cancer database analysis

Bronkema, Chandler; Arora, Sohrab; Keeley, Jacob; Rakic, Nikola; Sood, Akshay; Dalela, Deepansh; Jamil, Marcus; Peabody, James O.; Rogers, Craig G.; Menon, Mani; Abdollah, Firas

doi:10.1016/j.urolonc.2020.11.013

Cited by 3 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCa mainly occurs in older men aged 60-80 years old. [1,2] Primary PCa includes AAP, DAP, intraductal carcinoma, urothelial carcinoma, squamous cell carcinoma, and basal cell carcinoma. [3,4] DAP, as the second most common subtype, [5] was first reported by Melicow and Patcher in 1967.…”

Section: Discussionmentioning

confidence: 99%

“…Studies have shown that surgical treatment can achieve a longer survival time than radiotherapy or systemic chemotherapy, especially in patients with non-metastatic DAP. [1,21] Other studies have shown that radiotherapy can effectively reduce the risk of death in DAP patients without lymph node or distant metastases, and cancerspecific mortality is similar to that of patients undergoing radical surgery. [3,22] Importantly, compared with AAP, DAP is more invasive, has a shorter progression-free survival and a higher cancer-specific mortality, regardless of metastasis status or surgery.…”

Section: Discussionmentioning

confidence: 99%

“…It should be noted that the value of serial PSA measurement is limited in terms of prediction of recurrence or metastasis. [1,7,11] Some studies have shown that patients with DAP who maintain low PSA levels may also have local recurrence or metastasis. [8] For this reason, clinicians should pay attention to imaging examinations in the long-term management of DAP patients.…”

Section: Discussionmentioning

confidence: 99%

“…Prostate cancer (PCa) is a common malignant tumor of the male genitourinary system. [1,2] The main pathologic type of primary PCa is acinar adenocarcinoma of the prostate (AAP), accounting for more than 90% of cases. [3] Ductal adenocarcinoma of the prostate (DAP) is second only to AAP, accounting for about 0.5%-3.2% of cases.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Ductal adenocarcinoma of the prostate or seminal vesicle adenocarcinoma: An multi-disciplinary team (MDT) case report and literature review

Hao

Song

et al. 2022

Current Urology

View full text Add to dashboard Cite

We introduced a 61-year-old male with ductal adenocarcinoma of the prostate who underwent a tortuous diagnosis and treatment. Multi-disciplinary team meetings organized by our hospital have shown great value in the whole process. The patient presented with gross hematuria accompanied by frequent urination initially, and was diagnosed with ductal adenocarcinoma of the prostate involving right seminal vesicle gland and urethra by urethroscopy biopsy. The clinical stage of tumor was T3bN0M0. After 4 cycles of neoadjuvant chemotherapy, the tumor shrank significantly and the patient underwent a laparoscopic radical prostatectomy. But the patient declined to continue chemotherapy postoperatively. After 10 months, the serum prostatic specific antigen increased to 0.05 ng/mL, and multiple metastases were found in the patient's bilateral lungs. However, an unexpected diagnosis of seminal vesicle adenocarcinoma was put forward from another hospital after supplementary pathologic immunohistochemical examination. Then, after careful discussion and demonstration by our multi-disciplinary team experts, we insisted on the diagnosis of ductal adenocarcinoma of the prostate and suggested that the original regimen of chemotherapy should be continued. Up-to-date, 14 months after the operation, the patient continues to survive while undergoing ongoing active treatment as recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Ductal adenocarcinoma of the prostate or seminal vesicle adenocarcinoma: An multi-disciplinary team (MDT) case report and literature review

Hao

Song

et al. 2022

Current Urology

View full text Add to dashboard Cite

show abstract

“…Prostate ductal adenocarcinoma (PDA) represents a rare variant of prostate cancer in patients with non-metastatic as well as metastatic disease, and regardless of the stage, PDA behaves more aggressively and has a high mortality rate [ 1 , 2 ]. The disease has been associated with a higher likelihood of extra-prostatic extension compared with acinar adenocarcinoma, positive surgical margins, and shorter time to recurrence after radical prostatectomy [ 2 - 4 ].…”

Section: Purposementioning

confidence: 99%

Very high-risk locally advanced prostate ductal adenocarcinoma cured using low-dose-rate brachytherapy, with seminal vesicle implantation in combination with external beam radiotherapy at a biologically effective dose ≥ 220 Gy: two case reports with a long-term follow-up

Okamoto¹

2022

jcb

View full text Add to dashboard Cite

Purpose: Prostate ductal adenocarcinoma (PDA) is an aggressive, rare variant of histologic sub-type of prostate cancer. Patients with PDA present with more aggressive clinical features and have a poorer prognosis than patients with acinar adenocarcinoma. So far, an optimal treatment for PDA has yet to be established. Furthermore, the effectiveness of low-dose-rate (LDR) brachytherapy for PDA has not been reported previously.Case presentation: In this paper, we present two case reports on very high-risk locally advanced PDA, in which patients were successfully treated with LDR brachytherapy, with seminal vesicle implantation in combination with external beam radiotherapy (EBRT) at a biologically effective dose (BED) ≥ 220 Gy and short-term androgen deprivation therapy (ADT). There was no grade 2 genitourinary (GU) and gastrointestinal (GI) toxicities during follow-up, and no evidence of hematuria nor rectal bleeding during follow-up. The patients stay healthy without biochemical failure and without bowel or urinary difficulties at 11.5 years and 8 years, respectively.Conclusions: High-BED LDR-based radiotherapy in combination with EBRT (BED ≥ 220 Gy) may be an ideal treatment for very high-risk locally advanced PDA patients.

show abstract

Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review

Marra¹,

Leenders²,

Zattoni³

et al. 2023

European Urology

View full text Add to dashboard Cite

Impact of treatment modality on overall survival in localized ductal prostate adenocarcinoma: A national cancer database analysis

Cited by 3 publications

References 19 publications

Ductal adenocarcinoma of the prostate or seminal vesicle adenocarcinoma: An multi-disciplinary team (MDT) case report and literature review

Ductal adenocarcinoma of the prostate or seminal vesicle adenocarcinoma: An multi-disciplinary team (MDT) case report and literature review

Very high-risk locally advanced prostate ductal adenocarcinoma cured using low-dose-rate brachytherapy, with seminal vesicle implantation in combination with external beam radiotherapy at a biologically effective dose ≥ 220 Gy: two case reports with a long-term follow-up

Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review

Contact Info

Product

Resources

About